Plain-English translation of NCT06916520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether prasugrel, a blood thinner medication, can be used alone at a lower dose after you receive a stent to open a blocked heart artery. Normally, patients take two blood thinners together (aspirin and another medication) after a stent, but this study is checking whether the medication alone might work just as well while causing fewer bleeding problems.
Current treatment with two blood thinners works well to prevent blood clots around stents, but it increases the risk of dangerous bleeding. New stent designs and improved understanding of heart disease suggest that this medication alone at a lower dose might provide the same heart protection with less bleeding risk.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the new treatment (prasugrel alone) or the standard treatment (two blood thinners together) after your stent is placed. You will take your assigned medication once daily and visit the study center for check-ups to monitor your heart health and watch for any bleeding or other side effects. The study lasts 6 months for stable heart disease or 12 months for heart attack patients.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Netherlands